19 research outputs found
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues
MicroRNAs (miRNAs) belong to a family of small nonâcoding RNAs (sncRNAs) playing important roles in human carcinogenesis. Multiple investigations reported miRNAs aberrantly expressed in several cancers, including highâgrade serous ovarian carcinoma (HGSâOvCa). Quantitative PCR is widely used in studies investigating miRNA expression and the identification of reliable endogenous controls is crucial for proper data normalization. In this study, we aimed to experimentally identify the most stable reference sncRNAs for normalization of miRNA qPCR expression data in HGSâOvCa. Eleven putative reference sncRNAs for normalization (U6, SNORD48, miRâ92aâ3p, letâ7aâ5p, SNORD61, SNORD72, SNORD68, miRâ103aâ3p, miRâ423â3p, miRâ191â5p, miRâ16â5p) were analysed on a total of 75 HGSâOvCa and 30 normal tissues, using a highly specific qPCR. Both the normal tissues considered to initiate HGSâOvCa malignant transformation, namely ovary and fallopian tube epithelia, were included in our study. Stability of candidate endogenous controls was evaluated using an equivalence test and validated by geNorm and NormFinder algorithms. Combining results from the three different statistical approaches, SNORD48 emerged as stably and equivalently expressed between malignant and normal tissues. Among malignant samples, considering groups based on residual tumour, miRâ191â5p was identified as the most equivalent sncRNA. On the basis of our results, we support the use of SNORD48 as best reference sncRNA for relative quantification in miRNA expression studies between HGSâOvCa and normal controls, including the first time both the normal tissues supposed to be HGSâOvCa progenitors. In addition, we recommend miRâ191â5p as best reference sncRNA in miRNA expression studies with prognostic intent on HGSâOvCa tissues
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence
<p>Abstract</p> <p>Background</p> <p>Traditional prognostic factors in epithelial ovarian cancer (EOC) are inadequate in predicting recurrence and long-term prognosis, but genome-wide cancer research has recently provided multiple potentially useful biomarkers. The gene codifying for Mammaglobin B (MGB-2) has been selected from our previous microarray analysis performed on 19 serous papillary epithelial ovarian cancers and its expression has been further investigated on multiple histological subtypes, both at mRNA and protein level. Since, to date, there is no information available on the prognostic significance of MGB-2 expression in cancer, the aim of this study was to determine its prognostic potential on survival in a large cohort of well-characterized EOC patients.</p> <p>Methods</p> <p>MGB-2 expression was evaluated by quantitative real time-PCR in fresh-frozen tissue biopsies and was validated by immunohistochemistry in matched formalin fixed-paraffin embedded tissue samples derived from a total of 106 EOC patients and 27 controls. MGB-2 expression was then associated with the clinicopathologic features of the tumors and was correlated with clinical outcome.</p> <p>Results</p> <p>MGB-2 expression was found significantly elevated in EOC compared to normal ovarian controls, both at mRNA and protein level. A good correlation was detected between MGB-2 expression data obtained by the two different techniques. MGB-2 expressing tumors were significantly associated with several clinicopathologic characteristics defining a less aggressive tumor behavior. Univariate survival analysis revealed a decreased risk for cancer-related death, recurrence and disease progression in MGB-2-expressing patients (p < 0.05). Moreover, multivariate analysis indicated that high expression levels of MGB-2 transcript (HR = 0.25, 95%, 0.08â0.75, p = 0.014) as well as positive immunostaining for the protein (HR = 0.41, 95%CI, 0.17â0.99, p = 0.048) had an independent prognostic value for disease-free survival.</p> <p>Conclusion</p> <p>This is the first report documenting that MGB-2 expression characterizes less aggressive forms of EOC and is correlated with a favorable outcome. These findings suggest that the determination of MGB-2, especially at molecular level, in EOC tissue obtained after primary surgery can provide additional prognostic information about the risk of recurrence.</p
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues.
11nonenoneRomani C;Calza S;Todeschini P;Tassi RA;Zanotti L;Bandiera E;Sartori E;Pecorelli S;Ravaggi A;Santin AD;Bignotti ERomani, Chiara; Calza, Stefano; Todeschini, Paola; Tassi, Renata Alessandra; Zanotti, Laura; Bandiera, Elisabetta; Sartori, Enrico; Pecorelli, Sergio; Ravaggi, Antonella; Santin, Alessandro; Bignotti, Elian
Identification of Optimal Reference Genes for Gene Expression Normalization in a Wide Cohort of Endometrioid Endometrial Carcinoma Tissues
<div><p>Accurate normalization is a primary component of a reliable gene expression analysis based on qRT-PCR technique. While the use of one or more reference genes as internal controls is commonly accepted as the most appropriate normalization strategy, many qPCR-based published studies still contain data poorly normalized and reference genes arbitrarily chosen irrespective of the particular tissue and the specific experimental design. To date, no validated reference genes have been identified for endometrial cancer tissues. In this study, 10 normalization genes (GAPDH, B2M, ACTB, POLR2A, UBC, PPIA, HPRT1, GUSB, TBP, H3F3A) belonging to different functional and abundance classes in various tissues and used in different studies, were analyzed to determine their applicability. In total, 100 endometrioid endometrial cancer samples, which were carefully balanced according to their tumor grade, and 29 normal endometrial tissues were examined using SYBR Green Real-Time RT-PCR. The expression stability of candidate reference genes was determined and compared by means of geNorm and NormFinder softwares. Both algorithms were in agreement in identifying GAPDH, H3F3A, PPIA, and HPRT1 as the most stably expressed genes, only differing in their ranking order. Analysis performed on the expression levels of all candidate genes confirm HPRT1 and PPIA as the most stably expressed in the study groups regardless of sample type, to be used alone or better in combination. As the stable expression of HPRT1 and PPIA between normal and tumor endometrial samples fulfill the basic requirement of a reference gene to be used for normalization purposes, HPRT1 expression showed significant differences between samples from low-grade and high-grade tumors. In conclusion, our results recommend the use of PPIA as a single reference gene to be considered for improved reliability of normalization in gene expression studies involving endometrial tumor samples at different tumor degrees.</p></div
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.
BACKGROUND: The aim of the present study was to investigate within ovarian carcinoma and normal ovarian biopsies the gene expression of multiple secretoglobin family members relative to mammaglobin B, which we previously reported as a promising novel ovarian carcinoma prognostic marker. METHODS: Using quantitative real-time Reverse Transcription PCR we tested 53 ovarian carcinoma and 30 normal ovaries for the expression of 8 genes belonging to the secretoglobin family: mammaglobin A, lipophilin A, lipophilin B, uteroglobin, HIN-1, UGRP-1, RYD5 and IIS. Next, we decided to expand the LipB gene expression analysis to a further 48 ovarian carcinoma samples, for a total of 101 tumor tissues of various histologies and to study its protein expression by immunohistochemistry in formalin-fixed paraffin-embedded tumors and normal ovaries. Finally, we correlated lipophilin B gene and protein expression to conventional patient clinico-pathological features and outcome. RESULTS: We found significant mammaglobin A, lipophilin A, lipophilin B and RYD5 gene overexpression in ovarian carcinomas compared to normal ovaries. Lipophilin B mRNA showed a higher presence in tumors (75.4%) compared to normal ovaries (16.6%) and the most significant correlation with mammaglobin B mRNA (r(s) =0.77, pâ<â0.001). By immunohistochemical analysis, we showed higher lipophilin B expression in the cytoplasm of tumor cells compared to normal ovaries (pâ<â0.001). Moreover, lipophilin B gene overexpression was significantly associated with serous histology (serous vs clear cell pâ=â0.027; serous vs undifferentiated pâ=â0.007) and lower tumor grade (pâ=â0.02). Lower LipB mRNA levels (low versus high tertiles) were associated to a shorter progression-free (pâ=â0.03, HRâ=â2.2) and disease-free survival (pâ=â0.02, HRâ=â2.5) by univariate survival analysis and, importantly, they remain an independent prognostic marker for decreased disease-free (pâ=â0.001, HRâ=â3.9) and progression-free survival (pâ=â0.004, HRâ=â2.8) in multivariate Cox regression analysis. CONCLUSIONS: The present study represents the first quantitative evaluation of secretoglobin gene expression in normal and neoplastic ovarian tissues. Our results demonstrate lipophilin B gene and protein upregulation in ovarian carcinoma compared to normal ovary. Moreover, lipophilin B gene overexpression correlates with a less aggressive tumor phenotype and represents a novel ovarian carcinoma prognostic factor
Candidate reference genes selected for evaluation of expression stability.
<p>Candidate reference genes selected for evaluation of expression stability.</p
Candidate reference genes for normalization listed according to their expression stability calculated by the NormFinder program.
<p>High expression stability is indicated by a low stability value as an estimation of both the intra- and the intergroup variation of individual gene, according to the model-based approach developed by Andersen et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0113781#pone.0113781-Andersen1" target="_blank">[17]</a>.</p><p>Candidate reference genes for normalization listed according to their expression stability calculated by the NormFinder program.</p
Expression levels of candidate reference genes in malignant (hatched boxes) and non-malignat (open boxes) endometrial samples.
<p>Values are given as calibrated normalized relative quantities (CNRQ). Boxes indicate IQR for the data of unmatched samples in each group.</p
Clinical and pathologic characteristics of 100 EC and 29 NE patients.
<p>Clinical and pathologic characteristics of 100 EC and 29 NE patients.</p